Jump to main content Jump to sidebar

blurb.social: Discover the web

Forums

Log in
Sign up

Search

Search query

50 results for www.fiercepharma.com:

Takeda hypes up dengue vaccine launch progress as Vyvanse generics loom - FiercePharma

fiercepharma.com

Submitted by fiercepharma5012 on July 27, 2023 at 5:38 PM in health

No comments

63

Biogen pays $7.3B to acquire Reata and newly approved Skyclarys - FiercePharma

fiercepharma.com

Submitted by fiercepharma5012 on July 28, 2023 at 3:17 PM in business

No comments

9

Pfizer, Opko gain FDA nod for weekly growth hormone drug Ngenla - FiercePharma

fiercepharma.com

Submitted by fiercepharma5012 on June 28, 2023 at 2:42 PM in business

No comments

27

Obesity drug shortage expands to Saxenda as Novo Nordisk warns of limited supply for 2023 and beyondWeight-loss drug shortage expands to Novo's Saxenda - FiercePharma

fiercepharma.com

Submitted by fiercepharma5012 on July 19, 2023 at 3:24 PM in health

No comments

12

Merck applies more pressure against IRA, asking for decision without trial in fight with US government - FiercePharma

fiercepharma.com

Submitted by fiercepharma5012 on July 12, 2023 at 3:14 PM in business

No comments

16

Regeneron's high-dose Eylea hit with surprise FDA rejection over manufacturing hiccupsRegeneron's high-dose Eylea hit with surprise FDA rejection over manufacturing hiccups - FiercePharma

fiercepharma.com

Submitted by fiercepharma5012 on June 27, 2023 at 9:14 PM in business

No comments

6

After metastatic disease win, Merck's Keytruda flunks trial in early stomach cancerAfter metastatic disease win, Merck's Keytruda flunks trial in early stomach cancer - FiercePharma

fiercepharma.com

Submitted by fiercepharma5012 on June 22, 2023 at 1:50 PM in business

No comments

60

NICE puts kibosh on Mounjaro coverage over GLP-1 comparison and cost model uncertainties - FiercePharma

fiercepharma.com

Submitted by fiercepharma5012 on June 27, 2023 at 3:16 PM in health

No comments

48

AstraZeneca forecasts stronger China sales as CEO tries to clear the air on spinoff reportAstraZeneca forecasts stronger China sales as CEO tries to clear the air on spinoff report - FiercePharma

fiercepharma.com

Submitted by fiercepharma5012 on July 28, 2023 at 3:06 PM in business

No comments

40

In approving Sarepta's DMD gene therapy, FDA's Peter Marks overruled reviewers' rejection - FiercePharma

fiercepharma.com

Submitted by fiercepharma5012 on June 26, 2023 at 3:35 PM in business

No comments

45

AstraZeneca hit with FDA warning letter over 'misleading' Breztri efficacy claims - FiercePharma

fiercepharma.com

Submitted by fiercepharma5012 on August 16, 2023 at 9:28 AM in business

No comments

49

FDA blesses CellTrans' Lantidra, the first cell therapy for Type 1 diabetesFDA blesses CellTrans' Lantidra, the first cell therapy for Type 1 diabetes - FiercePharma

fiercepharma.com

Submitted by fiercepharma5012 on June 29, 2023 at 2:27 PM in business

No comments

35

GSK’s Arexvy to lead new RSV vaccines sales race with Moderna a close second: reportGSK's Arexvy to lead new RSV vaccines sales race with Moderna a close second: report - FiercePharma

fiercepharma.com

Submitted by fiercepharma5012 on July 24, 2023 at 2:44 PM in health

No comments

60

Novartis to buy back $15B in shares despite Entresto setback - FiercePharma

fiercepharma.com

Submitted by fiercepharma5012 on July 18, 2023 at 3:05 PM in business

No comments

1

Apellis attempts to clear the air around Syfovre safety as eye drug launch gains steam - FiercePharma

fiercepharma.com

Submitted by fiercepharma5012 on July 31, 2023 at 2:22 PM in business

No comments

42

FDA signs off on UCB's myasthenia gravis drug Rystiggo - FiercePharma

fiercepharma.com

Submitted by fiercepharma5012 on June 27, 2023 at 3:28 PM in business

No comments

17

EMA will monitor suicide risk in Novo Nordisk's GLP-1 products - FiercePharma

fiercepharma.com

Submitted by fiercepharma5012 on July 10, 2023 at 3:11 PM in business

No comments

53

J&J, GSK's ViiV tout switching study showing patients prefer their long-acting HIV med Cabenuva over Gilead rival - FiercePharma

fiercepharma.com

Submitted by fiercepharma5012 on July 25, 2023 at 1:32 PM in health

No comments

40

GSK-funded report on adult vaccination rates ⁠finds major global declines in recent years - FiercePharma

fiercepharma.com

Submitted by fiercepharma5012 on July 19, 2023 at 6:59 PM in health

No comments

34

Oh doctor, J&J sues physicians who say baby powder causes cancer - FiercePharma

fiercepharma.com

Submitted by fiercepharma5012 on July 14, 2023 at 2:30 PM in business

No comments

20

GSK beats Merck to first PD-1 approval in newly diagnosed endometrial cancerGSK beats Merck to first PD-1 approval in newly diagnosed endometrial cancer - FiercePharma

fiercepharma.com

Submitted by fiercepharma5012 on July 31, 2023 at 6:42 PM in business

No comments

17

Merck still eyeing M&A and has plenty of firepower to execute it - FiercePharma

fiercepharma.com

Submitted by fiercepharma5012 on August 1, 2023 at 3:25 PM in business

No comments

1

Pfizer unveils potential cost-cutting measure on low COVID sales - FiercePharma

fiercepharma.com

Submitted by fiercepharma5012 on August 1, 2023 at 5:45 PM in business

No comments

60

The Ad Council teams up with the Alzheimer's Association for Hispanic dementia awareness push - FiercePharma

fiercepharma.com

Submitted by fiercepharma5012 on August 16, 2023 at 2:42 PM in health

No comments

13

MSF calls out GSK's ViiV for nondisclosure clauses in contract - FiercePharma

fiercepharma.com

Submitted by fiercepharma5012 on August 17, 2023 at 6:54 PM in health

No comments

28

Moderna present strong preliminary data for updated COVID shot - FiercePharma

fiercepharma.com

Submitted by fiercepharma5012 on August 18, 2023 at 3:06 PM in business

No comments

10

GSK stays a step ahead in RSV vaccine battle as Arexvy becomes available at US pharmaciesGSK says RSV shot Arexvy has arrived at major US pharmacies - FiercePharma

fiercepharma.com

Submitted by fiercepharma5012 on August 17, 2023 at 2:55 PM in health

No comments

30

On blockbuster mission, Merck says Welireg hit endpoint in renal cell carcinoma trial - FiercePharma

fiercepharma.com

Submitted by fiercepharma5012 on August 18, 2023 at 3:12 PM in business

No comments

38

After Regeneron scores FDA nod for high-dose Eylea, it’s game on in showdown with Roche’s VabysmoFDA approves Regeneron's HD Eylea, triggering battle with Roche - FiercePharma

fiercepharma.com

Submitted by fiercepharma5012 on August 21, 2023 at 3:01 PM in business

No comments

61

FDA approves Pfizer's Abrysvo for pregnancy to protect babies - FiercePharma

fiercepharma.com

Submitted by fiercepharma5012 on August 22, 2023 at 3:17 PM in health

No comments

58

Bayer survey reveals deep-seated fears of Americans around cancer as pharma looks to plug education gapBayer survey reveals deep-seated fears of Americans around cancer as pharma looks to plug education gap - FiercePharma

fiercepharma.com

Submitted by fiercepharma5012 on August 22, 2023 at 2:22 PM in health

No comments

36

Before key Tagrisso showdown, J&J notches Rybrevant trial win in large lung cancer area - FiercePharma

fiercepharma.com

Submitted by fiercepharma5012 on September 6, 2023 at 3:35 PM in business

No comments

18

Cabometyx study ends early after researchers see 'dramatic' benefits in neuroendocrine tumors, Exelixis says - FiercePharma

fiercepharma.com

Submitted by fiercepharma5012 on August 24, 2023 at 4:57 PM in business

It's not always a good thing when a drug developer stops a cancer trial

No comments

22

Novartis files suit against IRA after blockbuster Entresto makes CMS' price negotiations list - FiercePharma

fiercepharma.com

Submitted by fiercepharma5012 on September 5, 2023 at 3:17 PM in business

No comments

2

Ovarian Cancer Research Alliance to boost screening for new Ovarian Cancer Awareness Month campaign - FiercePharma

fiercepharma.com

Submitted by fiercepharma5012 on September 5, 2023 at 1:20 PM in health

No comments

29

Data breach flagged at J&J's patient assistance program: IBM - FiercePharma

fiercepharma.com

Submitted by fiercepharma5012 on September 6, 2023 at 10:59 PM in business

No comments

40

AbbVie's Skyrizi deals heavy blow to J&J's Stelara in head-to-head Crohn's disease study - FiercePharma

fiercepharma.com

Submitted by fiercepharma5012 on September 12, 2023 at 3:26 PM in business

No comments

38

BMS aims for staggering 25 label expansions in the coming years - FiercePharma

fiercepharma.com

Submitted by fiercepharma5012 on September 15, 2023 at 4:04 PM in business

No comments

39

Sanofi, Ice-T partner on 'unique and edgy' flu vaccine campaign - FiercePharma

fiercepharma.com

Submitted by fiercepharma5012 on September 13, 2023 at 12:15 PM in health

No comments

56

Novo Nordisk Foundation to set up cell therapy production 'hub' - FiercePharma

fiercepharma.com

Submitted by fiercepharma5012 on September 21, 2023 at 1:30 PM in business

No comments

61

Novartis makes sculptures to shape knowledge of cancer symptoms, laying groundwork for Jakavi use - FiercePharma

fiercepharma.com

Submitted by fiercepharma5012 on September 18, 2023 at 12:10 PM in health

No comments

29

Lilly pursues pharmacies, spas selling compounded Mounjaro - FiercePharma

fiercepharma.com

Submitted by fiercepharma5012 on September 20, 2023 at 1:31 PM in business

No comments

15

Takeda to pull lung cancer med Exkivity around the world after confirmatory trial flop - FiercePharma

fiercepharma.com

Submitted by fiercepharma5012 on October 4, 2023 at 1:55 PM in business

No comments

57

After 2 FDA rejections and restructuring drive, Intercept sells itself to Italy's Alfasigma - FiercePharma

fiercepharma.com

Submitted by fiercepharma5012 on September 26, 2023 at 3:10 PM in business

No comments

19

Merck's Lagevrio may have triggered new COVID variants: experts - FiercePharma

fiercepharma.com

Submitted by fiercepharma5012 on September 26, 2023 at 1:35 PM in health

No comments

32

Fierce 50: Breakthroughs honorees - FiercePharma

fiercepharma.com

Submitted by fiercepharma5012 on October 3, 2023 at 8:00 AM in business

No comments

10

Fierce 50: Innovation honorees - FiercePharma

fiercepharma.com

Submitted by fiercepharma5012 on October 3, 2023 at 8:00 AM in business

No comments

36

Eli Lilly slapped with third FDA rejection in 2023, this time for eczema treatment lebrikizumab - FiercePharma

fiercepharma.com

Submitted by fiercepharma5012 on October 3, 2023 at 3:06 PM in business

No comments

38

In splitting from Novartis, Sandoz makes muted market debut - FiercePharma

fiercepharma.com

Submitted by fiercepharma5012 on October 5, 2023 at 3:16 PM in business

No comments

62

Study shows Novo's Ozempic, Wegovy pose risk of stomach problems - FiercePharma

fiercepharma.com

Submitted by fiercepharma5012 on October 7, 2023 at 4:55 PM in news

No comments

36

We love you.